Phase 3 Readouts — Q1 2027
Phase 3 clinical trial readouts are pivotal moments for biotech companies. These large-scale trials (1,000-5,000+ patients) determine whether a drug has enough evidence of efficacy and safety to seek FDA approval.
92 phase 3 readouts in Q1 2027. Updated .
Phase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit
SINOVAC BIOTECH LTD (SVA)
Phase 3 Topline: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on L
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Phase 3 Topline: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or
FATE THERAPEUTICS INC (FATE)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolera
Vaxcyte, Inc. (PCVX)
Phase 3 Topline: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of
AbbVie Inc. (ABBV)
Phase 3 Topline: A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabru
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Ad
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retat
ELI LILLY & Co (LLY)
Phase 3 Topline: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose R
Grifols S.A. (GRFS)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Ven
Sanofi (SNY)
Phase 3 Topline: A Phase 3, Randomized Study, With Initial 24-week, Double-Blind and Placebo-Controlled Treatment Pha
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY
PFIZER INC (PFE)
Phase 3 Topline: A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Inve
Sanofi (SNY)
Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and
OCULAR THERAPEUTIX, INC (OCUL)
Phase 3 Topline: Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients W
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Randomized, Double-Blind, Multi-Regional, Phase 3 Study to Evaluate the Efficacy and Safety of AP3
West Pharmaceutical Services Inc. (WST)
Phase 3 Topline: A Phase IIIb Single Arm, 2 Cohorts Study Assessing the Efficacy and Safety of Capivasertib+ Fulvestr
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With C
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombin
Sanofi (SNY)
Phase 3 Topline: A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study Wi
MoonLake Immunotherapeutics (MLTX)
Phase 3 Topline: A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Ef
AMGEN INC (AMGN)
Phase 3 Topline: A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (R
PFIZER INC (PFE)
Phase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subj
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 3 Topline: A Phase 3, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safe
Moderna, Inc. (MRNA)
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Ef
Novartis AG (NVS)
Phase 3 Topline: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment W
BeOne Medicines Ltd. (ONC)
Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 4
Definium Therapeutics Inc. (DFTX)
Phase 3 Topline: A Two-Arm Multicenter Clinical Trial to Investigate Efficacy and Safety of FID123472 Ophthalmic Solu
GH Research PLC (GHRS)
Phase 3 Topline: A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golim
GH Research PLC (GHRS)
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3 Study to Evaluate the Safety and Pharmacokinetics of Berotralstat Prophylaxis in Children
BIOCRYST PHARMACEUTICALS INC (BCRX)
Phase 3 Topline: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficac
Immunovant, Inc. (IMVT)
Phase 3 Topline: A Phase 3, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy and Safet
Cingulate Inc. (CING)
Phase 3 Topline: A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Nec
Valneva SE (VALN)
Phase 3 Topline: Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Mara
Mirum Pharmaceuticals, Inc. (MIRM)
Phase 3 Topline: Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth F
Amneal Pharmaceuticals, Inc. (AMRX)
Phase 3 Topline: A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to
MoonLake Immunotherapeutics (MLTX)
Phase 3 Topline: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abirate
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Belo
Novo Nordisk A/S (NVO)
Phase 3 Topline: Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radi
CG Oncology, Inc. (CGON)
Phase 3 Topline: An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of
Novartis AG (NVS)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Early in Hos
Novartis AG (NVS)
Phase 3 Topline: A Phase 3, Multi-Center, Randomized Study to Assess The Efficacy, Safety and Tolerability of Subreti
Ocugen, Inc. (OCGN)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Ritux
Adicet Bio, Inc. (ACET)
Phase 3 Topline: A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Toler
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Stu
ASTRAZENECA PLC (AZN)
Phase 3 Topline: ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib a
ASTRAZENECA PLC (AZN)
Phase 3 Topline: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatmen
AMGEN INC (AMGN)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povor
Incyte Corp. (INCY)
Phase 3 Topline: EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Stud
Novartis AG (NVS)
Phase 3 Topline: EPIK-B5: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination
Novartis AG (NVS)
Phase 3 Topline: A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, an
GILEAD SCIENCES, INC. (GILD)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy
Merck & Co., Inc. (MRK)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Toler
Vaxcyte, Inc. (PCVX)
Phase 3 Topline: Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity o
ARGENX SE (ARGX)
Phase 3 Topline: A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and S
AbbVie Inc. (ABBV)
Phase 3 Topline: A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Eff
AbbVie Inc. (ABBV)
Phase 3 Topline: An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients Wit
IONIS PHARMACEUTICALS INC (IONS)
Phase 3 Topline: An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of
IONIS PHARMACEUTICALS INC (IONS)
Phase 3 Topline: An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Tr
Atea Pharmaceuticals, Inc. (AVIR)
Phase 3 Topline: A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy
ELI LILLY & Co (LLY)
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17
ELI LILLY & Co (LLY)
Phase 3 Topline: A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Maj
Xenon Pharmaceuticals Inc. (XENE)
Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, 3-Arm Parallel Group Study to Evaluate the Effica
OCULAR THERAPEUTIX, INC (OCUL)
Phase 3 Topline: A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insul
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Ph
Praxis Precision Medicines, Inc. (PRAX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolera
Vaxcyte, Inc. (PCVX)
Phase 3 Topline: A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Perf
MediWound Ltd. (MDWD)
Phase 3 Topline: Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic,
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Ve
Filana Therapeutics Inc. (FLNA)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Pa
Incyte Corp. (INCY)
Phase 3 Topline: Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participant
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povor
Incyte Corp. (INCY)
Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group
Sanofi (SNY)
Phase 3 Topline: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of
Sanofi (SNY)
Phase 3 Topline: A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of
ASTRAZENECA PLC (AZN)
Phase 3 Topline: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE IN
PFIZER INC (PFE)
Phase 3 Topline: A Randomized Trial of the Insulin-only Bionic Pancreas in Cystic Fibrosis Related Diabetes
GH Research PLC (GHRS)
Phase 3 Topline: A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of A
Incyte Corp. (INCY)
Phase 3 Topline: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlima
ANAPTYSBIO, INC (ANAB)
Phase 3 Topline: A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therap
GH Research PLC (GHRS)
Phase 3 Topline: A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome
Quoin Pharmaceuticals, Ltd. (QNRX)
Phase 3 Topline: Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients
CHINA PHARMA HOLDINGS, INC. (CPHI)
Phase 3 Topline: A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Admini
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercia
Novartis AG (NVS)
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy and Safety of
BeOne Medicines Ltd. (ONC)